Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on POLO RESOURCES LTD. We currently have 2 research reports from 2 professional analysts.
|23Mar17 07:00||RNS||Blackham Resources - Investment Update|
|01Mar17 16:35||RNS||Price Monitoring Extension|
|15Feb17 11:06||RNS||IRONSTONE RESOURCES - INVESTMENT UPDATE|
|10Feb17 07:00||RNS||BLACKHAM RESOURCES - INVESTMENT UPDATE|
|25Jan17 07:00||RNS||Result of Annual General Meeting|
|30Dec16 07:00||RNS||NOTICE OF ANNUAL GENERAL MEETING|
|20Dec16 15:22||RNS||RESULTS FOR THE YEAR ENDED 30 JUNE 2016|
Frequency of research reports
Research reports on
POLO RESOURCES LTD
POLO RESOURCES LTD
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - N1S Trend spotting - Strategy update
08 Mar 17
In this new product we present some strategy theme updates arising out of our latest analysis of macro trends and economic data and our innovative Quant work. We also look at upcoming events and suggest topping up on some of our Best Ideas for 2017.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017